Phillips TJ - Search Results

1

Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma.

Tam CS, Opat S, Simpson D, Cull G, Munoz J, Phillips TJ, Kim WS, Rule S, Atwal SK, Wei R, Novotny W, Huang J, Wang M, Trotman J. Tam CS, et al. Among authors: phillips tj. Blood Adv. 2021 Jun 22;5(12):2577-2585. doi: 10.1182/bloodadvances.2020004074. Blood Adv. 2021. PMID: 34152395 Free PMC article. Clinical Trial.

2

Postibrutinib outcomes in patients with mantle cell lymphoma.

Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner-Johnston N, Rule S, Advani R, Iberri D, Phillips T, Spurgeon S, Kozin E, Noto K, Chen Z, Jurczak W, Auer R, Chmielowska E, Stilgenbauer S, Bloehdorn J, Portell C, Williams ME, Dreyling M, Barr PM, Chen-Kiang S, DiLiberto M, Furman RR, Blum KA. Martin P, et al. Blood. 2016 Mar 24;127(12):1559-63. doi: 10.1182/blood-2015-10-673145. Epub 2016 Jan 13. Blood. 2016. PMID: 26764355 Free article.

3

A single center phase II study of ixazomib in patients with relapsed or refractory cutaneous or peripheral T-cell lymphomas.

Boonstra PS, Polk A, Brown N, Hristov AC, Bailey NG, Kaminski MS, Phillips T, Devata S, Mayer T, Wilcox RA. Boonstra PS, et al. Am J Hematol. 2017 Dec;92(12):1287-1294. doi: 10.1002/ajh.24895. Epub 2017 Sep 25. Am J Hematol. 2017. PMID: 28842936 Free PMC article. Clinical Trial.

4

Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004).

Wang M, Schuster SJ, Phillips T, Lossos IS, Goy A, Rule S, Hamadani M, Ghosh N, Reeder CB, Barnett E, Bravo MC, Martin P. Wang M, et al. J Hematol Oncol. 2017 Nov 2;10(1):171. doi: 10.1186/s13045-017-0537-5. J Hematol Oncol. 2017. PMID: 29096668 Free PMC article.

5

Successful use of cytarabine and bendamustine in a patient with mantle cell lymphoma and acute renal failure using intermittent hemodialysis: A case report.

Ettleson M, Bongers KS, Vitale K, Perissinotti AJ, Phillips T, Marini BL. Ettleson M, et al. J Oncol Pharm Pract. 2019 Apr;25(3):731-734. doi: 10.1177/1078155217754244. Epub 2018 Jan 31. J Oncol Pharm Pract. 2019. PMID: 29385883

6

Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma.

Phillips TJ, Forero-Torres A, Sher T, Diefenbach CS, Johnston P, Talpaz M, Pulini J, Zhou L, Scherle P, Chen X, Barr PM. Phillips TJ, et al. Blood. 2018 Jul 19;132(3):293-306. doi: 10.1182/blood-2017-10-812701. Epub 2018 Apr 25. Blood. 2018. PMID: 29695516 Free PMC article. Clinical Trial.

7

A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma.

Phillips T, Barr PM, Park SI, Kolibaba K, Caimi PF, Chhabra S, Kingsley EC, Boyd T, Chen R, Carret AS, Gartner EM, Li H, Yu C, Smith DC. Phillips T, et al. Invest New Drugs. 2019 Apr;37(2):297-306. doi: 10.1007/s10637-018-0655-0. Epub 2018 Aug 22. Invest New Drugs. 2019. PMID: 30132271 Free PMC article. Clinical Trial.

8

Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies.

Forero-Torres A, Ramchandren R, Yacoub A, Wertheim MS, Edenfield WJ, Caimi P, Gutierrez M, Akard L, Escobar C, Call J, Persky D, Iyer S, DeMarini DJ, Zhou L, Chen X, Dawkins F, Phillips TJ. Forero-Torres A, et al. Among authors: phillips tj. Blood. 2019 Apr 18;133(16):1742-1752. doi: 10.1182/blood-2018-08-867499. Epub 2019 Feb 25. Blood. 2019. PMID: 30803990 Free PMC article. Clinical Trial.

9

Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma.

Herrera AF, Goy A, Mehta A, Ramchandren R, Pagel JM, Svoboda J, Guan S, Hill JS, Kwei K, Liu EA, Phillips T. Herrera AF, et al. Am J Hematol. 2020 Jan;95(1):18-27. doi: 10.1002/ajh.25659. Epub 2019 Nov 6. Am J Hematol. 2020. PMID: 31621094 Free PMC article. Clinical Trial.

10

Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma.

Kamdar M, Li H, Chen RW, Rimsza LM, Leblanc ML, Fenske TS, Shea TC, Barr PM, Phillips TJ, Leonard JP, Kahl BS, Friedberg JW, Smith SM. Kamdar M, et al. Among authors: phillips tj. Blood Adv. 2019 Oct 22;3(20):3132-3135. doi: 10.1182/bloodadvances.2019000526. Blood Adv. 2019. PMID: 31648328 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

733 results

Search Page

Filters